A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Show more Show less
Investor insights
Funding rounds participated in
$1.4M sweet spot round size
Investor type
Basic info
Industry
Sectors
Date founded
2021
Funding rounds raised
Total raised
$1.4M
from 2 investors over 1 rounds
Oniria Therapeutics raised $1.4M on June 11, 2023
Investors: Fundacion Botin and + 3 Other investors